4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Targeting Human Thrombus by Liposomes Modified with Anti-Fibrin Protein Binders

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Development of tools for direct thrombus imaging represents a key step for diagnosis and treatment of stroke. Nanoliposomal carriers of contrast agents and thrombolytics can be functionalized to target blood thrombi by small protein binders with selectivity for fibrin domains uniquely formed on insoluble fibrin. We employed a highly complex combinatorial library derived from scaffold of 46 amino acid albumin-binding domain (ABD) of streptococcal protein G, and ribosome display, to identify variants recognizing fibrin cloth in human thrombus. We constructed a recombinant target as a stretch of three identical fibrin fragments of 16 amino acid peptide of the Bβ chain fused to TolA protein. Ribosome display selection followed by large-scale Enzyme-Linked ImmunoSorbent Assay (ELISA) screening provided four protein variants preferentially binding to insoluble form of human fibrin. The most specific binder variant D7 was further modified by C-terminal FLAG/His-Tag or double His-tag for the attachment onto the surface of nanoliposomes via metallochelating bond. D7-His-nanoliposomes were tested using in vitro flow model of coronary artery and their binding to fibrin fibers was demonstrated by confocal and electron microscopy. Thus, we present here the concept of fibrin-targeted binders as a platform for functionalization of nanoliposomes in the development of advanced imaging tools and future theranostics.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: not found
          • Article: not found

          Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities

            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases

            Liposomes are closed bilayer structures spontaneously formed by hydrated phospholipids that are widely used as efficient delivery systems for drugs or antigens, due to their capability to encapsulate bioactive hydrophilic, amphipathic, and lipophilic molecules into inner water phase or within lipid leaflets. The efficacy of liposomes as drug or antigen carriers has been improved in the last years to ameliorate pharmacokinetics and capacity to release their cargo in selected target organs or cells. Moreover, different formulations and variations in liposome composition have been often proposed to include immunostimulatory molecules, ligands for specific receptors, or stimuli responsive compounds. Intriguingly, independent research has unveiled the capacity of several phospholipids to play critical roles as intracellular messengers in modulating both innate and adaptive immune responses through various mechanisms, including (i) activation of different antimicrobial enzymatic pathways, (ii) driving the fusion–fission events between endosomes with direct consequences to phagosome maturation and/or to antigen presentation pathway, and (iii) modulation of the inflammatory response. These features can be exploited by including selected bioactive phospholipids in the bilayer scaffold of liposomes. This would represent an important step forward since drug or antigen carrying liposomes could be engineered to simultaneously activate different signal transduction pathways and target specific cells or tissues to induce antigen-specific T and/or B cell response. This lipid-based host-directed strategy can provide a focused antimicrobial innate and adaptive immune response against specific pathogens and offer a novel prophylactic or therapeutic option against chronic, recurrent, or drug-resistant infections.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              EP-2104R: a fibrin-specific gadolinium-Based MRI contrast agent for detection of thrombus.

              Thrombus (blood clot) is implicated in a number of life threatening diseases, e.g., heart attack, stroke, pulmonary embolism. EP-2104R is an MRI contrast agent designed to detect thrombus by binding to the protein fibrin, present in all thrombi. EP-2104R comprises an 11 amino acid peptide derivatized with 2 GdDOTA-like moieties at both the C- and N-terminus of the peptide (4 Gd in total). EP-2104R was synthesized by a mixture of solid phase and solution techniques. The La(III) analogue was characterized by and 1D and 2D NMR spectroscopy and was found to have the expected structure. EP-2104R was found to be significantly more inert to Gd(III) loss than commercial contrast agents. At the most extreme conditions tested (pH 3, 60 degrees C, 96 hrs), less than 10% of Gd was removed from EP-2104R by a challenge with a DTPA based ligand, while the commercial contrast agents equilibrated within minutes to hours. EP-2104R binds equally to two sites on human fibrin (Kd = 1.7 +/- 0.5 microM) and has a similar affinity to mouse, rat, rabbit, pig, and dog fibrin. EP-2104R has excellent specificity for fibrin over fibrinogen (over 100-fold) and for fibrin over serum albumin (over 1000-fold). The relaxivity of EP-2104R bound to fibrin at 37 degrees C and 1.4 T was 71.4 mM(-1) s(-1) per molecule of EP-2104R (17.4 per Gd), about 25 times higher than that of GdDOTA measured under the same conditions. Strong fibrin binding, fibrin selectivity, and high molecular relaxivity enable EP-2104R to detect blood clots in vivo.
                Bookmark

                Author and article information

                Journal
                Pharmaceutics
                Pharmaceutics
                pharmaceutics
                Pharmaceutics
                MDPI
                1999-4923
                02 December 2019
                December 2019
                : 11
                : 12
                : 642
                Affiliations
                [1 ]Laboratory of Ligand Engineering, Institute of Biotechnology, Czech Academy of Sciences, v.v.i., BIOCEV Research Center, Průmyslová 595, 252 50 Vestec, Czech Republic; hana.petrokova@ 123456ibt.cas.cz (H.P.); milan.kuchar@ 123456ibt.cas.cz (M.K.)
                [2 ]Department of Pharmacology and Immunotherapy, Veterinary Research Institute, v.v.i., Hudcova 70, 621 00 Brno, Czech Republic; masek@ 123456vri.cz (J.M.); viteckova@ 123456vri.cz (A.V.W.); bartheldyova@ 123456vri.cz (E.B.); kulich@ 123456vri.cz (P.K.); hubatka@ 123456vri.cz (F.H.); kotoucek@ 123456vri.cz (J.K.); knotigova@ 123456vri.cz (P.T.K.); vohlidalova@ 123456vri.cz (E.V.); hezova@ 123456vri.cz (R.H.); maskova@ 123456vri.cz (E.M.);
                [3 ]Department of Biochemistry, Institute of Hematology and Blood Transfusion, U nemocnice 2094/1, 128 20 Praha 2, Czech Republic; Jana.Stikarova@ 123456uhkt.cz (J.Š.); Jan.Dyr@ 123456uhkt.cz (J.E.D.)
                [4 ]Malvern Instruments Ltd., Enigma Business Park, Grove Lane, Malvern WR14 1XZ, UK; Stuart.Macaulay@ 123456malvern.com
                [5 ]Department of Immunology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hněvotínská 3, 775 15 Olomouc, Czech Republic
                [6 ]The International Clinical Research Center ICRC and Neurology Department of St. Anne’s University Hospital in Brno, Pekařská 53, 656 91 Brno, Czech Republic; robert.mikulik@ 123456fnusa.cz
                Author notes
                [* ]Correspondence: petr.maly@ 123456ibt.cas.cz (P.M.); turanek@ 123456vri.cz (J.T.); Tel.: +420-325-873-763 (P.M.); +420-732-813-577 (J.T.)
                Author information
                https://orcid.org/0000-0002-8243-320X
                https://orcid.org/0000-0002-6984-1268
                https://orcid.org/0000-0002-8572-7246
                Article
                pharmaceutics-11-00642
                10.3390/pharmaceutics11120642
                6955937
                31810280
                455e81bf-d08a-4e88-aef2-25986aadc46c
                © 2019 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( http://creativecommons.org/licenses/by/4.0/).

                History
                : 02 October 2019
                : 26 November 2019
                Categories
                Article

                fibrin,thrombus targeting,thrombus imaging,binding protein,abd scaffold,liposome,combinatorial library,metallochelation,fibrinogen bβ chain

                Comments

                Comment on this article